- 询价
- MedChemExpress(MCE)
- 美国
- HY-L009
- 2025年12月05日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
货期：询盘
- 供应商：
MedChemExpress LLC
- 规格：
询盘
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Kinase Inhibitor Library
MCE 国际站：Kinase Inhibitor Library
Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.Kinase inhibitor library designed by MCE contains 2909 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.
Description & Advantages:
• A unique collection of 2909 phosphorylation kinase inhibitors/regulators for high throughput screening (HTS) and high content screening (HCS).
• The library contains compounds targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase).
• Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases.
• Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
• Structurally diverse, medicinally active, and cell permeable.
• Rich documentation with structure, IC50, and customer reviews.
• NMR and HPLC validated to ensure high purity.
• All compounds are in stock and continuously updated.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【求助】用蛋白激酶C-alpha抑制剂或蛋白激酶C-epsilon抑制剂来灌流组织块可行吗？
li2005wh 用蛋白激酶C-alpha抑制剂或蛋白激酶C-epsilon抑制剂来灌流组织块可行吗？蛋白激酶C-alpha抑制剂或蛋白激酶C-epsilon抑制剂能透过细胞膜吗？ 文竹竹 应该查阅相关试剂的说明书看看能否通过细胞膜 wzc2004 li2005wh 您好！我也做信号转导，我有几种蛋白酶抑制剂和活化剂，可以和您交换您的蛋白激酶C-alpha抑制剂和蛋白激酶C-epsilon
lingwu 酪氨酸激酶抑制剂PP1和PP2有什么区别？如何选择， 急切想知道，谢谢！ ylhuang0502 首先纠正一下， PP1和PP2都不是酪氨酸激酶的通用抑制剂，两者均为Src family kinase的选择性抑制剂。其中PP2更常用些，两者的差异很小，化学结构非常相似，两者均不是Src family kinase 特异性抑制剂，两者均可抑制别的激酶的活性，，比如： The Src
3 篇 Nature 连发，解决世纪难题，周期蛋白的毁灭调控蕴含癌症患者的新生
在 cyclin D 上，被泛素化标记的 cyclin D 将会被蛋白酶体降解。此外研究还发现，AMBRA1 缺失会导致 cyclin D 和 MYC 蛋白水平升高。cyclin D 与 CDK4/6 结合，使 RB1 蛋白磷酸化。磷酸化 RB1 释放 E2F 转录因子来驱动细胞周期进程所需基因的表达。在 AMBRA1 缺失的细胞中，cyclin D 也能与 CDK2 激酶形成复合物，使癌细胞能够抵抗 CDK4/6 抑制剂的治疗。高水平的 cyclin D 会促进细胞增殖，从而导致 DNA 损伤、复制应激
技术资料暂无技术资料 索取技术资料
